PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 14.7% in April
PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 14.7% in April
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 6,400 shares, a drop of 14.7% from the March 31st total of 7,500 shares. Based on an average daily volume of 131,500 shares, the days-to-cover ratio is presently 0.0 days.
Pure Bioscience，Inc.(场外交易平台：Pure-Get Rating)是4月份空头股数价格大幅下降的接受者。截至4月15日，空头股数共有6,400股，较3月31日的7,500股减少14.7%。以日均成交量131,500股计算，目前天数与回补比率为0.0天。
PURE Bioscience Price Performance
纯生物科学性价比
PURE stock remained flat at $0.09 during mid-day trading on Friday. The business's fifty day moving average is $0.13 and its 200 day moving average is $0.14. The firm has a market capitalization of $10.02 million, a P/E ratio of -2.25 and a beta of 0.21. PURE Bioscience has a one year low of $0.07 and a one year high of $0.24.
在周五午盘交易中，纯股票持平于0.09美元。该业务的50日移动均线切入位为0.13美元，200日移动均线切入位为0.14美元。该公司市值为1,002万美元，市盈率为-2.25，贝塔系数为0.21。Pure Bioscience的一年低点为0.07美元，一年高位为0.24美元。
PURE Bioscience (OTCMKTS:PURE – Get Rating) last posted its quarterly earnings results on Friday, March 17th. The company reported ($0.01) earnings per share for the quarter. PURE Bioscience had a negative net margin of 228.72% and a negative return on equity of 142.15%. The company had revenue of $0.40 million during the quarter.
Pure Bioscience(OTCMKTS：Pure-Get Rating)上一次公布季度收益是在3月17日星期五。该公司公布了本季度每股收益(0.01美元)。纯生物科学公司的净利润率为负228.72%，净资产回报率为负142.15%。该公司本季度的收入为40万美元。
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC bought a new position in shares of PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned 0.92% of PURE Bioscience at the end of the most recent quarter. Institutional investors own 0.92% of the company's stock.
一家机构投资者最近买入了一只新的纯生物科学股票头寸。根据IFG Consulting LLC最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件，该公司在第三季度购买了Pure Bioscience，Inc.(OTCMKTS：Pure-Get Rating)股票的新头寸。该基金购买了809,809股该公司股票，价值约161,000美元。截至最近一个季度末，IFG Consulting LLC拥有Pure Bioscience 0.92%的股份。机构投资者持有该公司0.92%的股票。
PURE Bioscience Company Profile
Pure Bioscience公司简介
(Get Rating)
(获取评级)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Pure Bioscience，Inc.致力于发现、开发和商业化用于病原体和卫生控制的专有抗菌产品。它提供以柠檬酸二氢银为基础的消毒和消毒产品。该公司由Michael L.Krall于1992年8月24日创立，总部设在加利福尼亚州的兰乔库卡蒙加。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- ExxonMobil Gushes To New Highs
- 免费获取StockNews.com关于纯生物科学的研究报告(PURE)
- 如何投资今年最受欢迎的食品杂货股
- 阵列技术将太阳耀斑带到2023年收益预测
- 利率上升前最适合投资的银行股
- 如何投资农田：7个简单的方法
- 埃克森美孚股价创新高
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得《纯生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pure Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。